PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer
(PCa), but its clinical use was promptly extended to detection, staging and therapy response …

Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …

Summary Background National Comprehensive Cancer Network guidelines consider 18 F-
fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

18F-labeled prostate-specific membrane antigen (PSMA)–ligand PET has several principal
advantages over 68Ga-PSMA-11. The purpose of this retrospective study was to evaluate …

Fibroblast activation protein inhibitor (FAPI) PET/CT is a new tool in the diagnostic workup of
cancer. With a growing volume of applications, pitfalls and common findings need to be …

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with
68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in …

Prostate cancer is the second most common cause of malignancy among men, with bone
metastasis being a significant source of morbidity and mortality in advanced cases …

Background The analysis aimed to compare the radiotracers [68 Ga]-Ga-PSMA-11 and [18
F]-F-PSMA-1007 intraindividually in terms of malignant lesions, mi (molecular-imaging) TNM …